Skip to main content
Premium Trial:

Request an Annual Quote

Life Science Sales, Currency Effects Pull Bio-Rad's Q1 Revenue Down 5 Percent

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the market close on Tuesday that its first-quarter revenues fell 5 percent on lower life science products sales and the negative effect of foreign currency translation.

The firm reported total revenues of $400.9 million for the three-month period ended March 31, compared to revenues of $422.2 million for the first quarter of 2008. The company said that excluding foreign currency effects, its revenues increased around 3 percent year over year.

Bio-Rad's life science products business had revenues of $140.3 million, down 9 percent year over year, or 3 percent on a constant currency basis. Sales of its diagnostic products were $257.5 million, down 2 percent, but up 7 percent on a constant currency basis.

Bio-Rad said that the life science segment was negatively affected by "a general slowness in the research market in the US and Europe."

The firm posted a profit of $30.3 million, or $1.10 per share, up from $26.5 million, or $.96 per share, for the first quarter of 2008.

Its R&D costs were nearly flat with the year before at $37.2 million versus $37.5 million, while its SG&A spending increased less than 1 percent to $140.3 million from $139.7 million.

Bio-Rad finished the quarter with $192.9 million in cash and cash equivalents and $30 million in short-term investments.

Filed under

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.